Evidence map›Paper›PMID 42699060›Full record

ArticleBone reports2026

Blockade of NLRP3 alleviates systemic lupus erythematosus-induced osteoporosis through dual modulation of osteogenesis and osteoclastogenesis.

Feifu Deng, Yuting Liao, Weixiong Guo, Xiangxin Zhong, Xiang Gao, Ahmad, Yanzhi Liu, Jinsong Wei

Abstract read
In one paragraph

Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Feifu DengOrthopedics department, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China.
Yuting LiaoKey Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, 524045, People's Republic of China.
Weixiong GuoOrthopedics department, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China.
Xiangxin ZhongOrthopedics department, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China.
Xiang GaoStem Cell Research and Cellular Therapy Center, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China.
AhmadKey Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, 524045, People's Republic of China.
Yanzhi LiuKey Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People's Hospital of Zhanjiang), Zhanjiang, 524045, People's Republic of China.
Jinsong WeiOrthopedics department, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease frequently associated with accelerated bone loss and osteoporosis. Emerging evidence implicates the NLRP3 inflammasome as a pivotal mediator of inflammation-driven bone remodeling dysregulation in SLE. This study investigates the therapeutic potential of targeting NLRP3 inhibition for SLE treatment using both a synthetic NLRP3 inhibitor (MCC950) and a natural NLRP3 inhibitor-oridonin, for its potential clinical translation. Using a combination of

Indexed as

Lupus erythematosusMCC950MRL/lpr miceNLRP3OridoninOsteoporosis

Identifiers

PMID42699060
PMCPMC13543794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.